Estimated Total Tumor mRNA Predicts Cancer Outcomes

Single-cell RNA (scRNA) sequencing studies have suggested that total mRNA content correlates with tumor phenotypes. Technical and analytical challenges, however, have so far impeded at-scale pan-cancer examination of total mRNA content.

Recent single-cell studies revealed that expansion of cell state heterogeneity in cancer cells arises largely independently of genetic variation, bringing new conceptual insights into longstanding topics of cancer cell plasticity and cancer stem cells. Knowledge of marker genes across cancers, total mRNA expression per tumor cell may represent a robust and measurable pan-cancer feature that warrants a systematic evaluation in patient cohorts.

A large international team of medical scientists led by MD Anderson Cancer Center (Houston, TX, USA) developed a method to quantify tumor-specific total mRNA expression (TmS) from bulk sequencing data, taking into account tumor transcript proportion, purity and ploidy, which are estimated through transcriptomic/genomic deconvolution. The team collected scRNA-seq data from ten patients, comprising three with colorectal adenocarcinoma, three with hepatocellular carcinoma, two with lung adenocarcinoma and two with pancreatic adenocarcinoma.

The investigators used a surrogate measure for total mRNA, and they found that cells with higher total mRNA counts were less differentiated, exhibiting a "stem-like" cell state, and were enriched in genes associated with stemness and epithelial-mesenchymal transition. The group developed a mathematical method for deconvoluting bulk DNA and RNA sequencing data to yield a quantitative metric, TmS, representing the per-cell, per-haploid genome total RNA expression for a tumor. They found that higher tumor-specific mRNA levels correlated with reduced progression-free survival and overall survival by taking that metric to a data set of 6,590 tumor samples from four large patient cohorts linked with long-term outcomes data.

The team observed an unexpected inversion of the relationship between TmS and outcome in four of the 12 cancer types they investigated based on the stage of the disease, including breast cancer subtypes. In those cancers, early-stage patients with high TmS levels had more favorable outcomes, possibly because the prognostic effect of TmS was modified by treatment. They found that high TmS was associated with increased disease-free survival in patients with ER-positive, HER2-negative breast cancer, even after adjusting for chemotherapy and Oncotype Dx risk status (Genomic Health, Inc, Redwood City, CA, USA.

Wenyi Wang, PhD, a professor and senior author of the study, said, “Across all 15 cancer types, we did find consistent signals that high levels of total mRNA expression in tumor cells correspond to a worse prognosis.” The study was published on June 13, 2022 in the journal Nature Biotechnology.

Related Links:
MD Anderson Cancer Center
Genomic Health, Inc

Visit expo >

Gold Member

Pharmacogenetics Panel

VeriDose Core Panel v2.0

Verification Panels for Assay Development & QC
Seroconversion Panels

New

Blood Gas and Chemistry Analysis System

Edan i500

New

Luteinizing Hormone Assay

DRG LH-Serum ELISA Kit